TOMI Secures $750K Deal with Eye Health Firm, Eyes $1.7M Expansion

  • TOMI closed a $750K deal with an unnamed global eye health company for SteraMist systems across two U.S. facilities.
  • The customer signed a recurring consumable agreement, establishing a contracted revenue stream.
  • Additional orders could bring total revenue to $960K–$1.7M by year-end 2026.
  • The progression follows a typical pattern: handheld units → facility expansion → integrated systems.
  • TOMI’s BIT Solution platform was validated after initial success at the first facility.

TOMI’s deal with a global eye health firm underscores the growing demand for automated disinfection in regulated manufacturing. The structured adoption—from handheld units to whole-room systems—mirrors trends in pharma and biotech, where performance validation drives facility-wide rollouts. The recurring consumable agreement also highlights a shift toward predictable revenue streams in the infection prevention market.

Execution Risk
Whether TOMI can convert prospective orders into actual revenue by year-end 2026.
Market Validation
How this deal’s progression model applies to other regulated manufacturing clients.
Recurring Revenue
The pace at which consumable agreements expand TOMI’s contracted revenue base.